These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10223433)

  • 1. Tardive dyskinesia: probing abnormal metabolism with promethazine.
    Bates GD; Lopes O; van Woerkom AE; Klovrza L; Waring R
    Acta Psychiatr Scand; 1999 Apr; 99(4):294-9. PubMed ID: 10223433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man.
    Taylor G; Houston JB; Shaffer J; Mawer G
    Br J Clin Pharmacol; 1983 Mar; 15(3):287-93. PubMed ID: 6849764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neuroleptic concentrations and tardive dyskinesia.
    Jeste DV; Linnoila M; Wagner RL; Wyatt RJ
    Psychopharmacology (Berl); 1982; 76(4):377-80. PubMed ID: 6126895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic-induced tardive dyskinesia.
    Jenner P; Marsden CD
    Acta Psychiatr Belg; 1987; 87(5):566-98. PubMed ID: 2897761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early course of new-onset tardive dyskinesia in older patients.
    Lacro JP; Gilbert PL; Paulsen JS; Fell R; Bailey A; Juels C; Caligiuri M; McAdams LA; Harris MJ; Jeste DV
    Psychopharmacol Bull; 1994; 30(2):187-91. PubMed ID: 7831454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Butaperazine pharmacokinetics in tardive dyskinesia.
    Wolf ME; Javaid JI; Mosnaim AD; Davis JM
    Biopharm Drug Dispos; 1985; 6(2):223-7. PubMed ID: 2860932
    [No Abstract]   [Full Text] [Related]  

  • 12. Tardive dyskinesia and plasma homovanillic acid.
    Moore DC; Glazer WM; Bowers MB; Heninger GR
    Biol Psychiatry; 1983 Dec; 18(12):1393-402. PubMed ID: 6140961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenylalanine kinetics are associated with tardive dyskinesia in men but not in women.
    Richardson MA; Reilly MA; Read LL; Flynn CJ; Suckow RF; Maher TJ; Sziraki I
    Psychopharmacology (Berl); 1999 Apr; 143(4):347-57. PubMed ID: 10367551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodiazepines for neuroleptic-induced tardive dyskinesia.
    Bhoopathi PS; Soares-Weiser K
    Cochrane Database Syst Rev; 2006 Jul; (3):CD000205. PubMed ID: 16855954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of severe tardive dyskinesia in Hungarian schizophrenic out-patients.
    Gardos G; Samu I; Kallos M; Cole JO
    Psychopharmacology (Berl); 1980; 71(1):29-34. PubMed ID: 6109346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of tardive dyskinesia.
    Gardos G; Cole JO; Haskell D; Marby D; Paine SS; Moore P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):31S-37S. PubMed ID: 2906068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human whole blood and parotid saliva concentrations of oral and intramuscular promethazine.
    DiGregorio GJ; Ruch E
    J Pharm Sci; 1980 Dec; 69(12):1457-9. PubMed ID: 7463341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects.
    Rao JM; Cowie VA; Mathew B
    Acta Psychiatr Scand; 1987 Nov; 76(5):507-13. PubMed ID: 2893512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.
    Lerer B; Segman RH; Tan EC; Basile VS; Cavallaro R; Aschauer HN; Strous R; Chong SA; Heresco-Levy U; Verga M; Scharfetter J; Meltzer HY; Kennedy JL; Macciardi F
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):411-25. PubMed ID: 15857569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.